A 3-in-1 Breakthrough in CAR-T Manufacturing

A new paper in Cytotherapy describes an integrated platform that may significantly accelerate how CAR-T cells are produced. Researchers from Terumo BCT and partners have developed a system that combines activation, transduction, and expansion into a single closed-loop hollow-fiber device.

This platform was tested using T cells from healthy donors and lymphoma patients. Results showed it could consistently yield CAR-T cells of high viability and functionality in just 8 days. Importantly, it avoids the need for centrifugation and open transfers, minimizing contamination risk.

The approach aims to reduce manual labor and variability across sites while maintaining GMP compliance. This innovation could enable faster delivery of personalized therapies in cancer and autoimmune diseases.

👉 Read the full article: A 3-in-1 integrated automated platform for rapid CAR-T cell manufacturing: activation, transduction, and expansion in a hollow-fiber system

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.